To deantigenate means to eliminate all elements that the immune system may recognise as antigens, thereby avoiding an undesired reaction. The Zymo-Teck® enzymatic treatment is based on the application of latestgeneration processes. A mixture of lytic enzymes in variable composition removes all antigenic components from the bone, making it completely biocompatible, yet preserving the collagen in its native conformation. This is why Bioteck® grafts have unique qualities, both in terms of biological response and clinical results. Visual evaluation of the deantigenation process Cycle I Biochemical Laboratory/Quality Control - Bioteck S.p.A. Bioteck S.p.A. Headquarters: Via E. Fermi 49 - 36057 Arcugnano (VI) - Italy Tel. +39 0444 289366 - fax: +39 0444 285272 [email protected] - www.bioteck.com Production and R&D Center: Via G. Agnelli, 3 - 10020 Riva presso Chieri (TO) - Italy Bioteck® is an Italian company producing bone substitutes and protective membranes that are successfully used in orthopaedics, neurosurgery, oral and maxillofacial surgery. Founded in 1995, the company continues to grow constantly and now operates in more than 50 countries around the world. A firm commitment to scientific research forms the basis for the innovative solutions offered by Bioteck® products. The company collaborates on numerous national and international research projects, which have driven the basic research and helped in writing important chapters in bone biology. The in-depth knowledge acquired by Bioteck® through its research ensures the absolute quality of its products, which are subjected to strict environmental and quality controls, thereby guaranteeing a product meeting the highest quality and safety standards. Bioteck® applies a policy of total transparency, opening up the doors of its Production and R&D Center for the monitoring of its innovative manufacturing process and the intense Production and R&D Center scientific research carried out by its staff. Quality and safety guarantee concept: mauro forlani - vi - cod. 20140516_ENG_DepliantOsteoPlant_Spine - printed by: www.abalti.it A unique, innovative deantigenation process total biocompatibility ideal osteoconduction complete remodeling The images clearly show the efficacy of the first three cycles of the Zymo-Teck® deantigenation process in cleaning the bone trabeculae, when applied to a block of cancellous equine bone. Biochemical Laboratory/Quality Control Quantification of the lipid content % LIPID RESIDUE Initial lipid content (residue of 100%) Osteoplant® - a complete range of cancellous and cortical bone grafts. Osteoplant® Flex - a line of exclusive grafts that are partially demineralized to leave them soft and flexible. Osteoplant® Activagen® and Angiostad® - bone pastes in syringe, malleable and injectable, with excellent osteoconductive and osteopromotion properties. Zymo-Teck®, Osteoplant®, Activagen®, Angiostad®, are all registered Bioteck S.p.A. trademarks. Biochemical Laboratory/Quality Control - Bioteck S.p.A. As can be seen from the graph, the first three treatment cycles of the ZymoTeck® process already suffice to ensure that almost all the lipid content is removed.

Enzymatic deantigenation Zymo-Teck : the secret of quality grafts ® preserves some important biological properties of bone Preserved collagen cancellous bone microgranules OGS-03A Cancellous bone granules OGS-05A Cancellous bone granules Bioteck® bone grafts are obtained from equine bone tissue treated with the Zymo-Teck® system, an exclusive multi-step deantigenation process that, by using specific enzyme mixtures, enables the elimination of all antigen components, keeping the mineral phase and bone collagen unchanged in its native conformation. The Zymo-Teck® process operates at controlled...